Showing results (31-40 of 48) with videos related to
Sort By:
Pageof 5
Human Genetics|July 1, 1997
Identification of novel 'expressed sequence tags' within the FHIT gene locus in human chromosome region 3p14.2A Lux, W Bardenheuer, D Michael, et al.Journal of the National Cancer Institute|September 24, 1999
Novel tumor suppressor locus in human chromosome region 3p14.2K Jülicher, G Marquitan, N Werner, et al.Genes, Chromosomes & Cancer|January 27, 1998
Minimal deletion of 3p13-->14.2 associated with immortalization of human uroepithelial cellsL Vieten, C D Belair, L Savelieva, et al.Cancer Chemotherapy and Pharmacology|January 1, 1993
Ifosfamide plus doxorubicin in previously untreated patients with advanced soft-tissue sarcomaJ Schütte, H T Mouridsen, W Steward, et al.European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Phase II study of nimustine in metastatic soft tissue sarcoma. European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma GroupD J Wagener, R Somers, A Santoro, et al.European Journal of Cancer (Oxford, England : 1990)|November 13, 2012
Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysisM Montemurro, H Gelderblom, U Bitz, et al.Seminars in Oncology|February 1, 1992
Experience with ifosfamide in the EORTC Soft Tissue and Bone Sarcoma GroupG Blackledge, W P Steward, J Verweij, et al.Cancer Research|June 13, 2000
Differential susceptibility of renal carcinoma cell lines to tumor suppression by exogenous Fhit expressionN S Werner, Z Siprashvili, L Y Fong, et al.European Journal of Cancer (Oxford, England : 1990)|January 1, 1990
Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma GroupJ Schütte, H T Mouridsen, W Stewart, et al.Annals of Hematology|December 2, 2000
Long-term survival after induction therapy with idarubicin and cytosine arabinoside for de novo acute myeloid leukemiaM Flasshove, P Meusers, J Schütte, et al.Pageof 5